Kidney Week

Abstract: FR-PO901

Serum MCP-1 and TGF-β as Biomarkers of Immunosuppressive Treatment Effectiveness in IgA Nephropathy

Session Information

• IgA Nephropathy: Clinical, Outcomes, and Therapeutics
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Jeon, Junseok, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)

Junseok Jeon, MD, PhD

• Yoon, Younmin, Chosun University Hospital, Chosun University School of Medicine, Gwang-ju, Korea (the Republic of)

Younmin Yoon, MD, PhD

• Lee, Kyungho, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)

Kyungho Lee, MD, PhD

• Lee, Jung eun, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)

Jung eun Lee, MD, PhD

• Huh, Wooseong, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)

Wooseong Huh, MD, PhD

• Jang, Hye Ryoun, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)

Hye Ryoun Jang, MD, PhD

Background

IgA nephropathy (IgAN) is the most common form of glomerulonephritis, and a significant proportion of patients progress to end-stage kidney disease. Predicting patient prognosis and response to immunosuppressive therapy is crucial for proper management. We aimed to investigate the clinical factors and biomarker for response to immunosuppressive therapy in patient with IgAN

Methods

This retrospective study included adult patients who were diagnosed with biopsy-proven IgAN between 2010 and 2020. Study variables included clinical and pathological variables and biomarkers, including serum and urine MCP-1, RANTES, TGF-beta, and VEGF, and tissue CD45+ cells. Outcome was the good prognosis defined as urine protein to creatinine ratio (uPCR) ≥ 50% reduction or < 0.5 mg/mg and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 or decrease < 5 mL/min/1.73 m² at one year from the kidney biopsy.

Results

Mean age, eGFR, and uPCR were 44.3 ± 12.7 and 42.0 ± 13.3 years; 56.9 ± 29.4 and 68.6 ± 30.7 mL/min/1.73 m²; 2.1 ± 1.6 and 1.6 ± 1.6 mg/mg in the control and gool prognosis groups, respectively. A good prognosis at one year is a good reflection of long-term renal outcomes. High body mass index, no hypertension, high eGFR, low uPCR, low histologic grade, and immunosuppressive therapy were predictors of good prognosis. After adjusting with clinical and pathological variables, lower serum MCP-1 and higher serum TGF-β were associated with good prognosis in patients with immunosuppressive therapy, but not with conservative therapy. The proportion of CD4+ cells were not associated with prognosis in patients with immunosuppressive therapy.

Conclusion

Immunosuppressive therapy was associated with good prognosis in patients with IgAN, although there may be selection bias. Serum MCP-1 and TGF-β have the potential to be biomarkers for the effectiveness of immunosuppressive therapy in patients with IgAN.

Funding

• Government Support – Non-U.S.